Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003897 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00003897 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants.
The verdict
NCT00003897, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL gp100 antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1999-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003897
The ClinicalTrials.gov registry entry for NCT00003897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00003897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003897 about?
NCT00003897 is a clinical study titled "Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma". RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.
What is the current status of trial NCT00003897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1999-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00003897?
The interventions under investigation include: sargramostim (BIOLOGICAL), gp100 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003897?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.